Healthcare entity
All 2 tracked stories fall under one category: market-trends. Of the tracked stories, 2 of 2 also mention Antengene Corporation Limited, the most common co-covered peer. Across a 173-day span, the pace is roughly 0.1 stories per week. Source depth averages 2 original sources per story, versus 3.4 across the same-window beat baseline.
Last mentioned: 4h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: market-trends. Of the tracked stories, 2 of 2 also mention Antengene Corporation Limited, the most common co-covered peer. Across a 173-day span, the pace is roughly 0.1 stories per week. Source depth averages 2 original sources per story, versus 3.4 across the same-window beat baseline. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. AnTenGager appears in 2 tracked Healthcare stories published from March 4, 2026 through August 23, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1034 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AnTenGager. Shared-story counts are live from our verified record — not editorial picks.
Press Release Distribution
Company issues PRNewswire release summarizing the summit highlights.
Evercore Summit Presentation
Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.
Clinical Filings Target
Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
Investor Briefings
Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
Global License Agreement
Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.
Source: admin (in) · admin (in)
AnTenGager is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
